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How this article was created 28 
We searched Medline and the Cochrane Library to identify published systematic reviews and 29 
randomised controlled trials on the diagnosis and management of uncomplicated urinary 30 
tract infections, including antibiotic benefits and harms, natural history of the condition, and 31 
commonly used alternative treatments (cranberry, urinary alkalisers, non-steroidal anti-32 
inflammatory drugs). We included journal articles identified in the references of articles from 33 
the initial search. We searched for relevant NICE guidelines on uncomplicated urinary tract 34 
infections. We have referred to recent systematic reviews and meta-analyses but have cited 35 
individual clinical studies where there is no higher quality of evidence. 36 
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How patients were involved in the creation of this article  42 
We discussed the article with 2 women who have had uncomplicated urinary tract infections 43 
and ensured that information was provided about whether alternatives to antibiotics work 44 
and that contained Box 5 safety-netting information and prompted that written information be 45 
provided. 46 
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Uncomplicated Urinary Tract Infection  64 
 65 
Vignette/case and introduction 66 
Your next patient is a 32 year old woman who thinks she has a urinary tract infection (UTI). 67 
She’s passing urine more frequently, has suprapubic pain and dysuria. After two days, it 68 
hasn’t improved.  69 
This article will outline how to identify uncomplicated UTI in adult non-pregnant women (18-70 
65 years) and discuss options with women to help them make an informed decision about its 71 
management.  72 
 73 
What you should cover  74 
Acute UTIs are very common community infections. They affect most women at least once in 75 
their life and far less prevalent among men.1-3 Women with an acute UTI present with 76 
diverse symptoms that can be burdensome and impact their quality of life.4 5  77 
 78 
What questions you should ask 79 
 80 
Take a history to determine risk factors for UTI and differentiate between uncomplicated 81 
UTIs and other causes of urinary symptoms. Recurrent UTI (when there are 3 or more UTIs 82 
within one year), asymptomatic bacteruria, or infection associated with an indwelling urinary 83 
catheter each require a different approach, not covered here. Symptoms and signs are 84 
described in box 1. Evidence from diagnostic studies supports the useful diagnostic value of 85 
commonly recognised symptoms such as dysuria, haematuria, nocturia, urgency and 86 
frequency, as well as those that decrease the probability that the patient has a UTI. 87 
Likelihood ratios of these symptoms are listed in box 2. However, no individual or 88 
combination of symptoms can make clinicians completely confident in diagnosing a UTI. 89 
Check for red flags suggestive of acute pyelonephritis or sepsis (box 3), which would require 90 
immediate management and/or referral to a hospital. 91 
 92 
Is examination necessary? 93 
In most cases of low-risk non-pregnant women with UTIs, clinical examination is not 94 
required, and the consultation can be safely conducted remotely. However, if the patient is 95 
systemically unwell and presents with any red flag symptom, arrange a physical 96 
examination. Assess the patient’s vital signs (temperature, blood pressure, heart rate, and 97 
respiratory rate) for signs of systemic illness or sepsis and palpate the abdomen and the 98 
back for flank or suprapubic tenderness.  99 
 100 
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 101 
Box 1. Questions to ask  
Is the patient experiencing: 
• Burning pain while urinating (dysuria)?  
• Urge to void immediately (urgency)? 
• Passing urine more than usual at night (nocturia)? Or passing urine more 
frequently in general (frequency)? 
• Cloudy urine visible to the naked eye or blood in the urine (haematuria)? 
Vaginal discharge and/or vaginal irritation?  (these symptoms are suggestive of a vaginal 
cause of urinary symptoms. Box 4 gives the most common differential diagnoses for 
UTIs.) 
NICE Guidelines state that patients with 2 or 3 of these key symptoms (cloudy urine, 
dysuria or new nocturia) are indicative of a UTI.9 10 However a systematic review of 16 
studies (3711 patients)11 identified visible haematuria (rather than cloudy urine), along with 
dysuria or new nocturia, as one of the diagnostic symptoms suggestive of UTI. 
 
Is there a history of:  
• recent sexual activity? (UTIs are very common among sexually active women.6) 
• previous UTI?  (The majority of women with a UTI reported a history of UTI 
infection during the 12 months prior to the current episode.7) 
• Using spermicidal agents or a diaphragm?  (Spermicidal agents affect the vaginal 
flora and the diaphragm increase the levels of introital and periurethral colonization 
with bacteria.8) 
• Current pregnancy? (UTIs are common during pregnancy)  




Box 2: Summary likelihood ratios (LR) of symptoms suggestive of an 
uncomplicated UTI11, 12 
Symptoms INCREASING the probability of 
UTI * 
Symptoms DECREASING the probability of 
UTI ** 
• Haematuria +LR 1.72 (95% CI 1.30 
to 2.27) 
• A history of vaginal discharge +LR 
0.3 (95% CI 0.1 to 0.9) 
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• Dysuria +LR 1.30 (95% CI 1.20 to 
1.41) 
• Nocturia +LR 1.30 (95% CI 1.08 to 
1.56) 
• Urgency +LR 1.22 (95% CI 1.11 to 
1.34) 
• Frequency +LR 1.10 (95% CI 1.04 
to 1.16) 
• A history of vaginal irritation +LR 0.2 
(95% CI 0.1 to 0.9) 
* All values reported for threshold of ≥102 CFU/ml, therefore probabilities at higher reference standards are 
lower. 
** Values reported for threshold of ≥105 CFU/ml 
 103 
 104 
Box 3: Red flags for acute pyelonephritis or sepsis 
Acute pyelonephritis6 13 Sepsis14  
• Flank pain (on the back, at 
and/or below level of ribcage)  
• Rigors or fever >37.9°C  
• Nausea/vomiting 
• New/different myalgia, flu-like 
illness 
• ≥ 21 breaths per minute 
• Heart rate: ≥ 91 beats per minute 
• Systolic blood pressure 91-100 mmHg 
or less than 90 mmHg (i.e. > 40 mmHg 
below normal) 
• Not passed urine in the past 12-18 
hours or more 
• Behaviour changes (acute 
deterioration, altered behaviour or 
mental state)  
 105 
What investigations might be needed? 106 
Urine dipstick tests are the most commonly used point of care test in primary care.15 For the 107 
laboratory diagnosis of UTI, dipstick results can modestly improve diagnostic precision, but 108 
cannot definitively rule out a UTI (Table 1). 109 
 110 
Box 4: Common differential diagnoses of urinary symptoms12 
• Vaginal infections (e.g., Trichomonas, Candida albicans, Gardnerella) 
• Vaginitis: post sexual intercourse, irritants 
• Sexually transmitted infections leading to pelvic inflammatory disease 
• Vulvovaginal atrophy 
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Dipstick urinalysis  Possibility of UTI Further 
testing Nitrite Leukocyte RBC 









+ + - 
+ - - Likely** 
- + + 
- + - Equally likely to other diagnosis 





*Positive predictive value (PPV) of 92% (95% CI 86 to 96%), which is the probability 
that patients with a positive test have a UTI. Cut-off point on dipstick score ≥3 (NPV= 
42%, 95% CI not reported).  
** Positive predictive value of 81% (95% CI= 77% to 84%). Cut-off point on dipstick 
score ≥ 2 (NPV =57%, 95% CI 52 to 62%) 
*** Negative predictive value (NPV) 76% (95% CI 66 to 84%) which is the probability 
that patients with a negative test truly do not have a UTI. Cut-off point on dipstick score 
≥1 
Urine dipstick cut-off score is based on the sum of nitrite = 2, leucocyte = 1.5, RBC = 
1. 
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t Growth cut-off thresholds used to define a UTI can vary (e.g. in some laboratories or 
countries, it may be ≥103 CFU/ml, whereas ≥105 CFU/ml in others). Culture results 
should also be interpreted with consideration of the severity of signs and symptoms. 
 111 
What you should do  112 
 113 
Constructing a shared decision making conversation 114 
In this scenario there are typically two main options that are reasonable to consider: 115 
immediate antibiotics or ‘wait and see’/delayed prescribing. To enable the patient to make an 116 
informed decision about the next steps, the clinician needs to explain both options to the 117 
patient, along with the benefits and harms of each, and discuss the patient’s preferences 118 
before making a shared decision.  An approach to this is suggested in box 5. 119 
 120 
What is the natural history of a UTI? 121 
There is uncertainty around the natural history of uncomplicated UTI, with few studies 122 
examining this. In a systematic review of the placebo-controlled arms of three randomised 123 
trials (346 placebo group participants), some women appeared to improve or become 124 
symptom free spontaneously, with most improvement occurring in the first 9 days.16 Over the 125 
first 9 days, the percentage of participants who were symptom free or reported improved 126 
symptoms was reported as rising to 42% and by 6 weeks, the percentage was 36%. Some 127 
women (39%) whose symptoms either failed to improve by 6 weeks or became worse over a 128 
variable timespan, although the rate of serious complications was low with progression to 129 
pyelonephritis was reported in one placebo participant in two of the trials. The low rate of 130 
serious complications supports the practice of delayed prescribing, where the patient is 131 
given a prescription but advised to wait to see whether symptoms self-resolve before 132 
antibiotics are commenced. 133 
 134 
An estimate of the mean duration of UTI symptoms is provided by an observational study of 135 
women with suspected uncomplicated UTI.18 In the 511 women who had seen a clinician for 136 
their symptoms and rated the initial problem as moderately bad or worse, the mean reported 137 
symptom duration was 3.8 days. However, most of the sample took antibiotics, with only 17 138 
participants (approximately 3%) who did not; their reported mean symptom duration was 4.9 139 
days. In a related 5-arm randomised trial, a similar duration of moderately bad or worse 140 
symptoms was reported: 3.5 days in the immediate antibiotic group and 4.8 days in the 141 
delayed (by 48 hours) prescription group.19 142 
How long can you 'wait and see' for? 143 
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The recommendation in the NICE guideline17 is to wait for 2 days before commencing 144 
antibiotics. However, there is no evidence provided in support of this timeframe and it is 145 
unclear whether the 2-day timeframe is from the start of symptoms or from first consultation. 146 
The findings from the systematic review16 suggest a 2-day timeframe may be too short, with 147 
few participants likely to have improved by then, although about a third may have improved 148 
by 7–10 days. There appears to be a lot of uncertainty and variability in the spontaneous 149 
recovery timeframe, and when ‘wait and see’ (delayed prescribing) is discussed with the 150 
patient as an option this should include careful description of when to reconsult or 151 
commence antibiotics (Box 5).   152 
The option of a delayed prescription will be acceptable to many patients. In a cohort study in 153 
Amsterdam, 37% of women who were asked by their general practitioner to delay antibiotic 154 
treatment were willing to do so,20 however no further details about how this option was 155 
presented to patients are provided.  156 
What difference do antibiotics make?  157 
Surprisingly, we could not find a synthesis of antibiotic versus placebo randomised controlled 158 
trials for uncomplicated UTI in women under 65 years and therefore no quantification of the 159 
effect, perhaps because antibiotic treatment is the traditional management of uncomplicated 160 
UTI.  The extent to which they reduce recovery time, reduce the risk of progression to 161 
pyelonephritis, and reduce the risk of recurrence is unknown and not presented in evidence-162 
based clinical practice guidelines.  163 
 164 
For the antibiotics most commonly prescribed for UTI (e.g. nitrofurantoin, trimethoprim), 165 
there does not appear to be synthesised evidence of their harms. For other antibiotics 166 
commonly prescribed in primary care, commonly reported adverse effects include diarrhoea, 167 
rash, and nausea.21 22 Candidiasis is also possible from antibiotic use. Another harm of 168 
antibiotic use is the contribution to antibiotic resistance. This is already particularly a problem 169 
for trimethoprim, with existing resistance rates of at least 30% of Escherichia coli isolates to 170 
trimethoprim.23 Patients with antibiotic-resistant E. coli UTI are significantly more like to 171 
experience clinical response failure (odds ratio [OR] 4.19 (95% confidence interval 3.27 to 172 
5.37); n = 2432 participants).24 173 
 174 
Despite being unable to quantify how much difference antibiotics make to UTI symptom 175 
duration, they are effective in treating the infection. Refer to the current NICE guideline for 176 
information about considerations about which antibiotic (guided by local antibiotic resistance 177 
patterns, where possible), and recommended dosage and duration.17  178 
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 179 
Other treatments  180 
There is little evidence to support the various over-the-counter medications that patients will 181 
often have tried prior to a consultation or concurrently with antibiotics. A 2016 Cochrane 182 
review of urinary alkalisers found no randomised trials.25 There are no randomised trials of 183 
cranberry for the treatment of uncomplicated UTI26 27 and a Cochrane review of cranberry 184 
products found they did not prevent recurrent urinary tract infections in women any more 185 
than placebo or no treatment (RR 0.86, 95% CI 0.71 to 1.04).28 186 
 187 
A systematic review of the effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs) 188 
compared to antibiotics for uncomplicated UTI found five randomised trials.29 For the 189 
outcome of symptom resolution, three trials found that NSAIDs were inferior to antibiotics; 190 
but two trials (smaller, with higher or unclear risk of bias) found no significant difference 191 
between the arms. In the groups that received NSAIDs, the percentage of women with 192 
symptom resolution by day 3 or 4 ranged from 39%-58%. In two of the three trials that 193 
reported pyelonephritis, rates were slightly higher in the NSAID group (risk difference of 4 194 
and 5 respectively).  195 
 196 
When to reconsult and when to refer  197 
Women with uncomplicated UTI without risk factors can be typically be assessed remotely. 198 
Box 5 contains safety-netting information to advise patients about when to commence 199 
antibiotics (if a delayed prescription was given) and/or reconsult and Box 3 lists the red flags 200 
for acute pyelonephritis and sepsis which are likely to require hospital admission.  201 
 202 
Box 5: Elements of a shared decision making conversation 
A shared decision making discussion following the diagnosis of an uncomplicated UTI 
typically involves the following (although it may not be a simple linear process as 
presented here): 
• Outline that there is choice about the next steps and a decision to be made; 
invite the patient to partner with you in the decision-making to the extent that the 
patient desires, and reassure any patient who feels overwhelmed or uncertain 
about the patient’s involvement or how to proceed; 
• Elicit the patient’s expectations about management of the condition. This can 
include previously tried treatments and experiences, along with fears and concerns 
(including symptom severity and how it may impact daily tasks); this allows for 
Copyright © 2021, BMJ Publishing Group Ltd 
Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or 
illustrative material included where another copyright owner is identified) is permitted strictly pursuant to the 
terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) 
detecting and discussing misperceptions, where necessary, either now or later in 
the process); 
• Explain the options 
- Wait and see (this may involve providing a delayed prescription for 
antibiotics and clear information about to when to use it) 
- Commence antibiotics immediately  
• Discuss the benefits and harms of the options (including their likely probability 
or size)  
- Describe the natural course of an uncomplicated UTI and that for some 
women, it will resolve within about a week without taking antibiotics. Also 
explain that there is uncertainty about exact timeframes and whether your 
patient will be one of the women who gets better without antibiotics (and that 
if not, antibiotics may need to be commenced later). 
- Discuss that antibiotics probably shorten the duration of symptoms, however 
by taking them, there is the risk of side effects and antibiotic resistance. 
- Regardless of which option is chosen, provide advice on symptom 
management (e.g. paracetamol or ibuprofen) 
• Provide the opportunity to weigh up the benefits and harms of the options, and 
consider them in the context of the patient’s preferences, values, and 
circumstances  
• Explore if the patient has any questions, is ready to make a decision, or needs 
further information, time, or the involvement of other people. 
• Provide safety-netting information about when to commence antibiotics (if 
delayed prescription) and/or reconsult 
- Nausea or vomiting 
- Rigors 
- Shivering, chills, and muscle pain 
- Feeling confused or very drowsy 
- Not passing urine all day 
- Blood in the urine 
- Temperature above 38ºC  
- Kidney pain in the back or under the ribs 
- Worsening UTI symptoms 
- If taking antibiotics, no improvement in UTI symptoms after 48 hours  
• Provide written patient information leaflet with summary information30  
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 203 
What you need to know 204 
• In about a third of women, an uncomplicated UTI may resolve on its own within about 205 
7-10 days, without the need for antibiotics  206 
• The option of ‘wait and see’ (which typically involves providing a delayed 207 
prescription) can be discussed as part of a shared decision making process within 208 
the consultation    209 
• Consider pyelonephritis or sepsis and hospital admission in patients who are 210 
systemically unwell and have high fever, rigours, nausea/vomiting, flank pain, low 211 
blood pressure, high heart rate, high respiratory rate, not passing urine for 12-18 212 
hours, and behaviour change 213 
 214 
Education into practice 215 
How do you invite patients to share in the decision-making about management of their 216 
uncomplicated UTI, including a discussion about their expectations? 217 
 218 
How can you facilitate a balanced discussion about the benefits and harms of using 219 
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